Effectiveness of Sacubitril–Valsartan in Cancer Patients with Heart Failure
Ana Martín‐Garcia(Complejo Hospitalario de Salamanca), Pedro L. Sánchez(Universidad de Salamanca), Amparo Martínez‐Monzonís(Instituto de Salud Carlos III), Cristina Mitroi(Sociedad Española de Nefrología), Agustín Martín‐García(Universidad de Salamanca), Marinela Chaparro‐Muñoz(Hospital Universitario Virgen Macarena), José López‐Sendón(Hospital Universitario La Paz), Teresa López‐Fernández(Hospital Universitario La Paz), Antonio Castro(Instituto de Salud Carlos III), Pedro Moliner(Bellvitge University Hospital)
Cited by 82
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
|New England Journal of Medicine|2019|945
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767